Cognition in schizophrenia: Past, present, and future

Abstract

Schizophrenia Research: Cognition will serve an important function - a place where interests converge and investigators can learn about the recent developments in this area. This new journal will provide rapid dissemination of information to people who will make good use of it. In this initial article, we comment globally on the study of cognition in schizophrenia: how we got here, where we are, and where we are going. The goal of this first article is to place the study of cognition in schizophrenia within a historical and scientific context. In a field as richly textured as ours it is impossible to hit all the important areas, and we hope the reader will forgive our omissions. Phrased in cognitive terms, our limited presentation of the past is a matter of selective memory, the present is a matter of selective attention, and the future is a matter of selective prospection. This broad introduction emphasizes that cognition in schizophrenia provides clues to pathophysiology, treatment, and outcome. In fact, the study of cognitive impairment in schizophrenia has become wholly intertwined with the study of schizophrenia itself.

Keywords: Cognition; History; Schizophrenia.

Conflict of interest statement

Conflict of interest

Dr. Green has been a consultant to AbbVie, Biogen, DSP, and Roche, and he is on the scientific advisory board of Mnemosyne. He has received research funds from Amgen. Dr. Harvey has received a contract research grant from Genentech, and has received honoraria for consulting or travel support from AbbVie, Boeheringer Ingelheim, En Vivo, Genentech, Otsuka America, Roche, Sunovion, Shire, and Takeda.